AnalystBook Research · Company Intelligence

Silexion Therapeutics Corp

SLXNNasdaq

Built from Silexion Therapeutics Corp's own SEC filings · updates as new filings land · sources cited throughout

or browse all covered companies

The read at a glance

Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.

  • Distress risk · Altman Z-Score -31.64 distress zone — historically elevated failure riskWatch

Leadership changes

From Silexion Therapeutics Corp's own filings, the day they're filed.

  • Professor Amnon Peled · Directors · departureeff. 2026-08-01
  • Professor Peled · departureeff. 2026-08-01
  • Ilan Shiloah · departureeff. 2024-11-19

Latest filings

  • 8-K · Company announcement2026-08-21
  • 10-Q · Quarterly report2026-08-14
  • 8-K · Company announcement2026-08-14
  • 8-K · Company announcement2026-08-13
  • 8-K · Company announcement2026-08-13
In the full recordFree for 14 days
  • The filings, readable — with what changed vs the prior year highlighted🔒
  • Full financial statements, industry-aware, sources cited throughout🔒
  • Forensic score history & components — the trend, not one year🔒
  • Ownership: insider buys/sells, clusters, activist stakes🔒
  • Ana — ask about Silexion Therapeutics Corp, every answer cited to the official filings🔒
  • The Intelligence Brief — added when Silexion Therapeutics Corp's brief passes our SEC-figure check🔒

Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.

14-day free trial, no credit card. For research purposes only; not investment advice.